242139-87-3

Basic information

• Product Name: (R)-N-[2-chloro-4-iodophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide
• Synonyms: (R)-N-[2-chloro-4-iodophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide
• CAS NO: 242139-87-3
• Molecular Weight: 393.532
• Mol File: 242139-87-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (R)-N-[2-chloro-4-iodophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-[2-chloro-4-iodophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide(242139-87-3)
• EPA Substance Registry System: (R)-N-[2-chloro-4-iodophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide(242139-87-3)

Safety Data

• Hazardous Substances Data: 242139-87-3(Hazardous Substances Data)

Upstream product

• 585-48-8 2,6-di-tert-butyl-pyridine 
• 79-37-8 oxalyl dichloride 
• 374-35-6 (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid 
• 42016-93-3 2-chloro-4-iodoaniline 

Downstream Products

• 252016-80-1 (R)-N-[2-chloro-4-(4-fluorophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide 
• 252016-79-8 (R)-N-[2-chloro-4-(2-fluorophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide 
• 252016-86-7 (R)-N-[2-fluoro-4-(2-fluorophenylthio)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide 
• 252019-49-1 (R)-N-(2-chloro-4-(triisopropylsilylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide 
• 252017-78-0 (R)-N-[2-chloro-4-(4-carboxyphenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide 
• 252018-14-7 (R)-N-[2-Chloro-4-(ethylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide 
• 252019-00-4 (R)-N-[2-Chloro-4-(2-hydroxyethylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide 
• 252018-18-1 (R)-N-[2-Chloro-4-(N-phenylcarbamoyl)phenyl]-2-hydroxy-2methyl-3,3,3-trifluoropropanamide 

Relevant articles and documents

Use of compounds for the elevation of pyruvate dehydrogenase activity

The use of compounds of the formula (I), and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs: wherein: Ring C is phenyl or a carbon linked heteroaryl ring substituted as defmed within; R1is an ortho substituent as defined within; n is 1 or 2; A—B is a linking group as defined within; R2and R3are as defined within; R4is hydroxy, hydrogen, halo, amino or methyl; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.